TITLE:

Palladium-Catalyzed Construction of Polycyclic Heterocycles by an Alkyne Insertion and Direct Arylation Cascade

AUTHOR(S):

Ohno, Hiroaki; Yamamoto, Mio; Iuchi, Mutsumi; Fujii, Nobutaka; Tanaka, Tetsuaki

CITATION:

Ohno, Hiroaki ...[et al]. Palladium-Catalyzed Construction of Polycyclic Heterocycles by an Alkyne Insertion and Direct Arylation Cascade. *Synthesis* 2011, 2011(16): 2567-2578

ISSUE DATE:

2011-07-08

URL:

<http://hdl.handle.net/2433/158034>

RIGHT:

© Georg Thieme Verlag Stuttgart • New York; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。

Palladium-Catalyzed Construction of Polycyclic Heterocycles by an Alkyne Insertion and Direct Arylation Cascade

Hiroaki Ohno,^{*a,b} Mio Yamamoto,^a Mutsumi Iuchi,^a Nobutaka Fujii,^b Tetsuaki Tanaka^{*a}

^a Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

^b Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

Fax: +81-6-6879-8214; E-mail: hohno@pharm.kyoto-u.ac.jp; t-tanaka@phs.osaka-u.ac.jp

Received: The date will be inserted once the manuscript is accepted.

Abstract: Cascade cyclization of bromoenynes bearing an aryl group with catalytic Pd(OAc)₂ and Cs₂CO₃ led to direct construction of tri- or tetracyclic heterocycles. Direct arylation of a pyrrole, furan or thiophene ring in the cascade reaction affords the corresponding fused heteroarenes in moderate to good yields.

Key words: tandem reaction, palladium, polycycles, fused-ring systems, ring closure

The development of cascade reactions that realize step-economical synthesis of complex compounds by multiple bond formation represents one of the most attractive subjects in modern organic chemistry.¹ Another challenge in this area is to improve atom economy by minimizing waste product formation.² C-H bond activation (including direct arylation), which avoids pre-activation of the substrate and thus minimizes the production of waste, is an important strategy for this purpose.³ As a result, considerable attention has been paid recently to catalytic cascade reactions including a C-H bond activation step.⁴

Palladium catalysts are well known to promote a variety of transformations including C-H bond activation. Several palladium-catalyzed cascade reactions have been reported recently, including carbopalladation onto a carbon-carbon multiple bond followed by C-H bond activation to form cyclic products.^{4,5} Reactions involving carbopalladation onto a carbon-carbon triple bond are especially useful for direct construction of fused aromatic ring systems^{6,7} such as oxindoles,^{6a,6b} fluorenes,^{6c} indoles,^{6d} phenanthrenes,^{6e} biarylidenes,^{7a,7b} acenaphthylenes,^{7c} and fused fulvenes.^{7d} We recently found that palladium-catalyzed cascade cyclization of bromoenynes **1** provides direct access to benzoisindole derivatives **2** (Scheme 1).⁸ This reaction proceeds through oxidative addition of a bromoenyne **1** to palladium(0), carbopalladation, and aromatic C-H bond activation. Herein, our detailed studies on this cascade cyclization including aromatic C-H bond activation for the synthesis of various tri- and tetracyclic heterocycles are reported. A reaction involving direct arylation with heteroarenes is also described.

Scheme 1 Synthesis of Isoindoles by Palladium-Catalyzed Cascade Reaction *via* C-H Bond Activation

The cinnamylamine-type bromoenynes **11** required for the cascade reaction were prepared according to the general route shown in Scheme 2. Carreira asymmetric alkynylation⁹ of aldehydes **5** with alkynes **6** gave propargylic alcohols **7**, which were converted to the corresponding protected propargylic amines **8** by Mitsunobu reaction with Boc-amides followed by acid treatment. In some cases, racemic propargylamines, which were readily prepared by reaction of lithium acetylide with aldehydes followed by amination, were used. A second Mitsunobu condensation with 2-bromocinnamyl alcohols **10**, which were obtained by Wittig reaction of aldehydes **9** followed by reduction with DIBAL-H, afforded the desired bromoenynes **11** in good yields. Other substrates were also prepared using a similar protocol (see the Supporting Information).

Scheme 2 General Syntheses of Substrates. Abbreviations: NME = *N*-methylmorpholine, DIAD = diisopropyl azodicarboxylate

First, the reaction conditions were optimized using bromoenyne **11a** (Table 1). After considerable experimentation, it was found that the conditions used by Oh *et al.*¹⁰ [cat. Pd(PPh₃)₄, Cs₂CO₃, EtOH] for a cascade cyclization–cross-coupling reaction of 2-bromo-1,6-enynes with an arylboronic acid promoted the desired bis-cyclization to give **12a**, albeit in low yield (26%, entry 1). Fortunately, use of Pd(OAc)₂ instead of Pd(PPh₃)₄ produced **12a** in 74% yield (entry 2). Decreasing the catalyst loading to 2 mol % slightly decreased the yield (64%, entry 3). A similar result was obtained using Pd₂(dba)₃·CHCl₃ as the catalyst (entry 5). Among several solvents examined, EtOH was the most effective (entries 3, 6, and 7). Other bases such as K₂CO₃ and NaOAc proved ineffective for the reaction.¹¹

Table 1 Optimization of Reaction Conditions Using Bromoenyne **11a**^a

entry	catalyst (mol %)	solvent	time (h)	yield (%) ^b
1	Pd(PPh ₃) ₄ (6)	EtOH	1	26
2	Pd(OAc) ₂ (6)	EtOH	2.5	74
3	Pd(OAc) ₂ (2)	EtOH	7	64
4	Pd(dppf) ₂ Cl ₂ (2)	EtOH	3.5	38
5	Pd ₂ (dba) ₃ ·CHCl ₃ (2)	EtOH	5	59
6 ^c	Pd(OAc) ₂ (2)	DMF	21	35
7	Pd(OAc) ₂ (2)	dioxane	21	27

^a Reactions were performed using Cs₂CO₃ (2 equiv). ^b Isolated yields. ^c The reaction was performed at 100 °C.

The reactions of various cinnamylamine-type enynes **11** using the optimized reaction conditions shown in entry 3 (Table 1) were investigated. The results of these reactions are summarized in Table 2. The influence of the substituent at the alkyne terminus was examined using *N*-tosylamides **11b–f**. 2-Hydroxypropan-2-yl, *n*-butyl, and unsubstituted derivatives **11b–d** gave the corresponding bis-cyclization products **12b–d** in 56–79% yield (entries 1–3). On the other hand, benzyloxymethyl derivative **11e** gave a complex mixture of unidentified products (entry 4). For an unclear reason, phenyl substitution also had a negative effect on the reaction, giving **12f** in just 27% yield (entry 5). Using different sulfonamide moieties (Ts vs. Ms) was relatively unimportant (Table 2, entry 3 vs. 6, and Table 2, entry 1 vs. Table 1, entry 3). In contrast, the reaction is sensitive to the substituent at the propargylic position (entries 7–11); unfortunately, substitution with a phenyl group was not tolerated (entry 7). The presence of a relatively bulky substituent such as an isopropyl or 1-siloxyethyl group at this position decreased the reaction yield (entries 10 and 11). When *tert*-butyl derivative **11j** was used (Scheme 3), only the monocyclization product **13j** was obtained in 7%

yield; the desired bis-cyclization product did not form. These bulky substituents might hamper the access of the palladium(II) intermediate of type **3** (Scheme 1) to the alkyne moiety. It should be noted that enynes **11m** and **11n** without propargylic or nitrogen substitution formed elimination products **14** (Scheme 3).¹² From these observations, the presence of both a substituent with appropriate bulkiness at the propargylic position and at the nitrogen atom are important for the cascade cyclization to proceed. Methoxy substitution at the *para*-position of the benzene ring decreased the reaction yield (37%, entry 13), while *meta*-methoxy substitution was tolerated (57%, entry 12).

Table 2 Synthesis of Benzoisindole Derivatives^a

entry	substrate	time (h)	product (yield) ^b
1	11b (R = CMe ₂ OH)	2.5	12b (64%)
2	(±)- 11c (R = <i>n</i> -Bu)	6	(±)- 12c (79%)
3	(±)- 11d (R = H)	2	(±)- 12d (56%)
4	11e (R = CH ₂ OBn)	1.5	12e (0%) ^c
5	11f (R = Ph)	6	12f (27%)
6	11g	6	12g (46%)
7	11h (R = Ph)	1	12h (0%) ^c
8	(±)- 11i (R = <i>n</i> -Pent)	3	(±)- 12i (65%)
9	(±)- 11k (R = <i>n</i> -Pent)	1.5	(±)- 12k (48%)
10	11l (R = <i>i</i> -Pr)	4	12l (24%)
11 ^d	11o	24	12o (39%)
12	11p (R ¹ = OMe, R ² = H)	5	12p (57%)
13	11q (R ¹ = H, R ² = OMe)	8	12q (37%)

^a Unless otherwise noted, reactions were carried out using Pd(OAc)₂ (2 mol %) and Cs₂CO₃ (2 equiv) in EtOH under reflux. ^b Isolated yields. ^c A complex mixture of unidentified products was formed. ^d An increased amount of Pd(OAc)₂ (4 mol %) was used.

Scheme 3 Unsuccessful Results using Bromoenynes **11j,m,n**.

Table 3 Synthesis of Tricyclic Heterocycles^a

entry	substrate	conditions ^b	product (yield) ^c
1		2 mol %, EtOH, 2 h	16a (43%)
2		10 mol %, DMF, 72 h	16b (27%) ^d
3		20 mol %, DMF, 2 h	16b (75%)
4		10 mol %, DMF, 2 h	16c (42%)
5		20 mol %, DMF, 2 h	16c (81%)
6		10 mol %, EtOH, 12 h	16c (36%)
7		10 mol %, EtOH, 12 h	16d (52%)
8		10 mol %, DMF, 3 h	16d (33%)
9		20 mol %, DMF, 4 h	16e (42%)

^a The reactions were carried out using Pd(OAc)₂ and Cs₂CO₃ (2 equiv) in EtOH (under reflux) or DMF (at 120 °C). ^b Catalyst loading, reaction solvent, and reaction time are shown. ^c Isolated yields. ^d The starting material was recovered (27%). Abbreviation: Mts = 2,4,6-trimethylbenzenesulfonyl.

To expand the reaction to construct various heterocyclic ring systems, the direct arylation¹³ of heterocyclic substrates **15a–e** was investigated (Table 3). The reaction of furan-substituted enyne **15a** was complete within 2 h to afford furo[2,3-*f*]isoindole **16a** in moderate yield (43%, entry 1). Bromoenynes **15b–e** bearing a pyrrole ring exhibited relatively low reactivity and thus required an increased loading of the palladium catalyst (entries 2–9). For example, the reaction of tosylamide **15b** with 10 mol % Pd(OAc)₂ and Cs₂CO₃ in DMF did not reach completion within 72 h, giving the desired tetrahydropyrrolo[3,4-*f*]indole **16b** in 27% yield along with the recovered starting material (entry 2). In contrast, the yield of **16b** was

improved to 75% when 20 mol % of the catalyst was used (entry 3). Similar results were obtained using *N*-Mts derivative **15c** (Mts = 2,4,6-trimethylbenzenesulfonyl, entries 4 and 5). It is worth noting that DMF was the solvent of choice for the reaction of protected pyrroles **15b** and **15c** because the reaction in EtOH was relatively inefficient and caused decomposition of the starting material (entry 6). When using electron-rich sulfonamide **15d**, the decomposition of the substrate in EtOH was suppressed to some extent, and the desired fused indole **16d** was produced in 52% yield (entry 7). The 2-position of the pyrrole was less reactive toward direct arylation than the 3-position in this cascade reaction (entry 3 vs. entry 9).

Table 4 Synthesis of Tetracyclic Heterocycles^a

entry	substrate	conditions ^b	product (yield) ^c
1		5 mol %, DMF, 18 h	18a (51%)
2		5 mol %, DMF, 3 h	18b (31%)
3		5 mol %, DMF, 4 h	18c (0%) ^d
4		5 mol %, EtOH, 1 h	18c (0%) ^e
5		10 mol %, EtOH, 36 h	18d (43%)
6		2 mol %, EtOH, 3 h	18e (49%)
7		2 mol %, EtOH, 1 h	18f (59%)
8		5 mol %, DMF, 5 h ^f	18g (43%)

^a Reactions were carried out using Pd(OAc)₂ and Cs₂CO₃ (2 equiv) in EtOH (under reflux) or DMF (at 120 °C). ^b Catalyst loading, reaction solvent, and reaction time are shown. ^c Isolated yields. ^d A complex mixture of unidentified products was formed. ^e The demethoxycarbonylation product was obtained (67%). ^f 2 h with 2 mol % catalyst and a further 3 h with an additional 3 mol % catalyst. Abbreviation: Mts = 2,4,6-trimethylbenzenesulfonyl.

The synthesis of tetracyclic fused ring systems was investigated next (Table 4). Among the protected indole-derived bromoenynes **17a–c** (entries 1–4), tosylate **17a** proved the most efficient substrate for the cascade reaction, giving the desired tetrahydropyrrolo[3,4-*b*]carbazole **18a** upon reaction in DMF (entry 1). The reaction of carbamate **17c** in EtOH only promoted demethoxycarbonylation of the substrate (entry 4). Interestingly, the electron-rich *N*-

methylindole-derived enyne **17d** was less reactive, affording **18d** in 43% yield using an increased loading of the palladium catalyst (10 mol %, entry 5). These results suggest that the direct arylation of indole derivatives **17** proceeds through a concerted metalation-deprotonation (CMD) pathway rather than electrophilic aromatic substitution (S_EAr).¹⁴ The reaction of benzothiophen-3-yl- and benzofuran-2-ynynes **17e** and **17f** produced the corresponding benzothiophene- and benzofuran-fused isoindoles **18e** and **18f**, respectively, in moderate yields (entries 6 and 7). 2,3-Dihydronaphtho[2,3-*f*]isoindole **18g** was obtained in 43% yield by activation of the naphthalene C-H bond (entry 8).

Finally, construction of an indane skeleton using malonate congeners **19** was investigated (Table 5). The reaction of **19a** with $Pd(OAc)_2$ in EtOH produced tricyclic carbocycle **20a** in 68% yield (entry 2). Other palladium catalysts such as $Pd_2(dba)_3 \cdot CHCl_3$ (entry 3) and $Pd(PPh_3)_4$ (entry 4) were less effective. The presence of a substituent at the propargylic position was important to promote the desired cascade cyclization also in the reactions using malonate derivatives.¹² The reaction of pyrrole-derived malonate **19b** in DMF at 140 °C resulted in the formation of cyclopenta[*f*]indole derivative **20b** in low yield (35%, entry 5).

Table 5 Synthesis of Indane Derivatives^a

entry	substrate	conditions ^b	product (yield) ^c
1	19a	5 mol %, DMF, 6 h	20a (0%) ^d
2	19a	5 mol %, EtOH, 2 h	20a (68%)
3	19a	5 mol %, ^e DMF, 4 h	20a (34%)
4	19a	5 mol %, ^f DMF, 4 h	20a (17%)
5	19b	5 mol %, DMF, 24 h ^g	20b (35%)

^a Unless otherwise stated, reactions were performed using $Pd(OAc)_2$ and Cs_2CO_3 (2 equiv) in EtOH (under reflux) or DMF (at 120 °C). ^b Catalyst loading, reaction solvent, and reaction time are shown. ^c Isolated yields. ^d A complex mixture of unidentified products was formed. ^e $Pd_2(dba)_3 \cdot CHCl_3$ was used. ^f $Pd(PPh_3)_4$ was used. ^g The reaction was conducted at 140 °C.

In conclusion, we have developed a palladium-catalyzed cascade for cyclization of bromoenynes. The reaction proceeds through carbopalladation onto a carbon-carbon triple bond and C-H bond activation of a benzene ring, leading to the direct construction of isoindole derivatives. The presence of a propargylic substituent is quite important for the progress of the reaction. Direct arylation of heteroarenes such as pyrrole, furan, thiophene and their benzene-fused rings allows various types of tri- and tetracyclic

heterocycles to be produced from readily prepared enynes.

Melting points are uncorrected. Nominal (LRMS) and exact mass (HRMS) spectra were recorded on a JEOL JMS-700 or JMS-600 mass spectrometer. ¹H NMR spectra were recorded in $CDCl_3$. Chemical shifts are reported in parts per million downfield from internal Me_4Si (s = singlet, d = doublet, dd = double doublet, ddd = doublet of double doublet, t = triplet, dt = double triplet, tt = triple triplet, q = quartet, m = multiplet). Optical rotations were measured in $CHCl_3$ with a JASCO DIP-360 digital polarimeter. For flash chromatography, silica gel 60 H (silica gel for thin-layer chromatography, Merck) or silica gel 60 (finer than 230 mesh, Merck) was employed.

General procedure for Synthesis of Bromoenynes (**11**) by Condensation of Propargyl Amine Derivatives (**8**) with 3-Aryl-2-bromoprop-2-en-1-ols (**10**)

To a stirred mixture of protected propargylic amine **8** (ca. 3 mmol), alcohol **10** (2.2 equiv), and PPh_3 (2.2 equiv) in THF (30 mL) was added dropwise diisopropyl azodicarboxylate (DIAD; 2.2 equiv) at 0 °C. The mixture was stirred for 4 h at room temperature and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel with an eluent of *n*-hexane–EtOAc to give **11**.

General Procedure for the Palladium-Catalyzed Cascade Cyclization of Bromoenynes: Synthesis of (1*R*)-1-Cyclohexyl-9-(2-hydroxypropan-2-yl)-2-methylsulfonyl-2,3-dihydro-1*H*-benzo[*f*]isoindole (**12a**) (Table 1, Entry 3)

A mixture of **11a** (124 mg, 0.265 mmol), Cs_2CO_3 (173 mg, 0.531 mmol), and $Pd(OAc)_2$ (1.2 mg, 0.0531 mmol; 2 mol %) in EtOH (1.5 mL) was heated under reflux for 7 h. After cooling the mixture, saturated NH_4Cl was added. The mixture was then extracted with EtOAc and dried over $MgSO_4$. Concentration under reduced pressure gave an oily residue, which was purified by column chromatography over silica gel with *n*-hexane–EtOAc (10:1) to give **12a** (65.7 mg, 64% yield) along with an unidentified minor product (2.5 mg, 3% yield).

Compound **12a**: colorless oil; $[\alpha]_D^{28} +31.4$ (c 0.62, $CHCl_3$).

IR (KBr): 3545 (OH), 1336 (NSO₂), 1153 cm^{-1} (NSO₂).

¹H NMR (300 MHz, $CDCl_3$): δ = 0.90–1.28 (m, 5H), 1.58–1.85 (m, 6H), 1.96 (s, 3H, CMe), 2.03 (s, 3H, CMe), 2.55 (s, 3H, SO₂Me), 4.65 (dd, *J* = 16.8, 1.2 Hz,

¹H NMR (300 MHz, CDCl₃): δ = 4.80 (dd, *J* = 16.8, 1.2 Hz, 1H, NCHH), 5.97 (d, *J* = 1.2 Hz, 1H, 1-H), 7.42–7.50 (m, 2H, Ar), 7.61 (s, 1H, Ar), 7.79–7.82 (m, 1H, Ar), 8.25 (dd, *J* = 9.9, 2.7 Hz, 1H, Ar).

¹³C NMR (67.5 MHz, CDCl₃): δ = 26.2, 26.3, 26.7 (2C), 31.4, 32.6, 34.2 (2C), 47.0, 53.4, 71.9, 75.2, 120.8, 125.0, 125.1, 126.5, 129.0, 130.3, 134.6, 136.4, 137.3, 139.0.

MS (FAB): *m/z* (%) = 388 [MH⁺] (53), 154 (100).

HRMS–FAB: *m/z* [M + H]⁺ calcd for C₂₂H₃₀NO₃S: 388.1946; found: 388.1948.

Minor product: colorless oil; [α]_D²² –114 (*c* 0.14, CHCl₃).

IR (KBr): 3519 (OH), 1338 (NSO₂), 1159 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 1.10 (s, 3H, CMe), 1.15–1.96 (m, 12H), 1.31 (s, 3H, CMe), 2.79 (s, 3H, SO₂Me), 4.47 (d, *J* = 1.2 Hz, 2H), 5.84 (s, 1H, C=CH), 7.13–7.27 (m, 5H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 26.1, 26.2, 26.3, 27.5, 28.8, 29.1, 29.4, 34.5, 43.2, 49.7, 67.6, 70.8, 113.8, 127.4 (2C), 127.6, 128.7 (2C), 136.7, 138.6, 148.9, 149.3.

MS (FAB): *m/z* (%) = 410 (40) [M + Na⁺], 176 (100).

HRMS–FAB: *m/z* [M + Na]⁺ calcd for C₂₂H₂₉NNaO₃S: 410.1766; found: 410.1789.

(1R)-1-Cyclohexyl-9-(2-hydroxypropan-2-yl)-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzo[f]isoindole (12b)

Bromoene **11b** (124 mg, 0.227 mmol) was converted to **12b** (67.6 mg, 64% yield) and minor product (17.1 mg, 16% yield) by the reaction for 2.5 h.

12b: Colorless oil; [α]_D²³ +50.6 (*c* 0.60, CHCl₃).

IR (KBr): 3525 (OH), 1599 (naphthalene), 1340 (NHSO₂), 1161 cm^{–1} (NHSO₂).

¹H NMR (500 MHz, CDCl₃): δ = 0.86–1.94 (m, 11H), 1.76 (s, 3H, CMe), 1.96 (s, 3H, CMe), 2.12 (s, 3H, PhMe), 4.62 (d, *J* = 16.5 Hz, 1H, NCHH), 4.75 (d, *J* = 16.5 Hz, 1H, NCHH), 6.08 (d, *J* = 1.5 Hz, 1H, 1-H), 7.00 (d, *J* = 7.9 Hz, 2H, Ph), 7.35–7.40 (m, 3H, Ar), 7.64–7.70 (m, 3H, Ar), 8.14 (d, *J* = 8.5 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 21.3, 26.27, 26.30, 26.8 (2C), 31.5, 32.3, 33.7, 47.3, 53.5, 72.2, 75.1, 120.2, 124.6, 124.7, 126.4 (2C), 127.5, 128.8 (2C), 129.1, 130.1, 134.3, 135.1, 136.5, 137.4, 138.0, 143.0.

MS (FAB): *m/z* (%) = 464 (38) [M + H⁺], 380 (100).

HRMS–FAB: *m/z* [M + H]⁺ calcd for C₂₈H₃₄NO₃S: 464.2259; found: 464.2270.

Minor product: colorless crystals; Mp 152–154 °C (*n*-hexane–EtOAc); [α]_D²³ +280 (*c* 0.33, CHCl₃).

IR (KBr): 3523 (OH), 1344 (NHSO₂), 1166 cm^{–1} (NHSO₂).

¹H NMR (500 MHz, CDCl₃): δ = 0.86–1.98 (m, 11H), 1.00 (s, 3H, CMe), 1.20 (s, 3H, CMe), 2.41–2.43 (m, 1H), 2.53 (s, 3H, PhMe), 4.36 (s, 1H), 4.41 (s, 1H), 5.93 (s, 1H, C=CH), 6.66 (d, 2H, *J* = 7.3 Hz, Ar), 7.13–7.35 (m, 5H, Ar), 7.66 (d, 2H, *J* = 8.5 Hz, Ph).

¹³C NMR (67.8 MHz, CDCl₃): δ = 21.8, 26.2, 26.35, 26.42, 27.8, 29.0, 29.1, 29.2, 43.1, 49.4, 67.3, 70.6, 114.0, 127.2, 127.4 (2C), 128.0 (2C), 128.2 (2C), 129.4 (2C), 133.2, 137.1, 138.5, 143.3, 148.5, 149.1.

MS (FAB): *m/z* (%) = 464 (56) [M + Na⁺], 154 (100).

HRMS–FAB: *m/z* [M + Na]⁺ calcd for C₂₈H₃₃NNaO₃S: 486.2074; found: 486.2079.

Anal. Calcd for C₂₈H₃₃NO₃S: C, 72.54; H, 7.17; N, 3.02. Found: C, 72.50; H, 7.19; N, 2.99.

(±)-9-Butyl-1-cyclohexyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzo[f]isoindole (12c)

Bromoene **11c** (130 mg, 0.240 mmol) was converted to **12c** (87.8 mg, 79% yield) by the reaction for 6 h.

Colorless oil; IR (KBr): 1346 (NSO₂), 1163 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.90–2.16 (m, 18H), 2.38 (s, 3H, PhMe), 2.81–2.91 (m, 1H, 1'-CHH), 2.95–3.05 (m, 1H, 1'-CHH), 4.71 (d, *J* = 16.2 Hz, 1H, 3-CHH), 4.83 (d, *J* = 16.2 Hz, 1H, 3-CHH), 5.12 (s, 1H, 1-H), 6.99 (d, *J* = 8.1 Hz, 2H, Ph), 7.34–7.46 (m, 3H, Ar), 7.57 (d, *J* = 8.1 Hz, 2H, Ph), 7.70 (d, *J* = 7.5 Hz, 1H, Ar), 7.92 (d, *J* = 8.1 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 14.0, 21.3, 23.2, 26.1, 26.4, 26.5, 26.7, 29.5, 31.5, 32.9, 45.4, 54.9, 70.4, 118.6, 124.0, 125.3, 125.4, 127.2 (2C), 128.5, 129.3 (2C), 131.5, 132.6, 133.6, 135.1, 135.8, 136.8, 143.1.

MS (FAB): *m/z* (%) = 462 (60) [M + H⁺], 378 (100).

HRMS–FAB: *m/z* [M + H]⁺ calcd for C₂₉H₃₆NO₂S: 462.2467; found: 462.2467.

(±)-1-Cyclohexyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzo[f]isoindole (12d)

Bromoene **11d** (63.9 mg, 0.131 mmol) was converted to **12d** (29.7 mg, 56% yield) by the reaction for 2 h.

Colorless oil; IR (KBr): 1346 (NSO₂), 1161 cm^{–1} (NSO₂).

¹H NMR (270 MHz, CDCl₃): δ = 0.89–1.34 (m, 5H), 1.50–1.75 (m, 6H), 2.24 (s, 3H, PhMe), 4.74 (d, *J* = 15.5 Hz, 1H, 3-CHH), 4.78 (d, *J* = 15.5 Hz, 1H, 3-CHH), 5.02 (d, *J* = 4.3 Hz, 1H, 1-H), 7.10 (d, *J* = 8.4 Hz, 2H, Ph), 7.41–7.44 (m, 2H, Ar), 7.53 (d, *J* = 9.5 Hz, 2H, Ar), 7.64 (d, *J* = 8.4 Hz, 2H, Ph), 7.71–7.79 (m, 2H, Ar).

¹³C NMR (68 MHz, CDCl₃): δ = 21.5, 26.2, 26.3, 26.5, 28.2, 28.8, 45.9, 53.8, 70.6, 120.4, 121.8, 125.7, 125.8,

127.0 (2C), 127.5, 127.9, 129.4 (2C), 132.6, 132.8, 135.2, 135.8, 137.9, 143.1.

MS (FAB): m/z (%) = 406 (70) [M + H⁺], 322 (100).

HRMS–FAB: m/z [M + H]⁺ calcd for C₂₅H₂₈NO₂S: 406.1841; found: 406.1823.

(1R)-1-Cyclohexyl-2-(4-methylphenylsulfonyl)-9-phenyl-2,3-dihydro-1H-benzo[f]isoindole (12f)

Bromoene **11f** (64.0 mg, 0.114 mmol) was converted to **12f** (15.0 mg, 27% yield) by the reaction for 6 h.

Colorless oil; $[\alpha]_D^{25}$ –46.5 (c 0.60, CHCl₃).

IR (KBr): 1346 (NSO₂), 1163 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.83–1.05 (m, 6H), 1.22–1.64 (m, 5H), 2.25 (s, 3H, PhMe), 4.75 (d, J = 16.5 Hz, 1H, 3-CHH), 4.93 (d, J = 16.5 Hz, 1H, 3-CHH), 5.02 (d, J = 2.4 Hz, 1H, 1-H), 6.94–6.97 (m, 1H, Ar), 7.13 (d, J = 8.4 Hz, 2H, Ph), 7.28–7.74 (m, 2H, Ar), 7.41 (dd, J = 8.1, 8.1 Hz, 1H, Ar), 7.48–7.51 (m, 5H, Ar), 7.66 (d, J = 8.4 Hz, 2H, Ph), 7.76 (d, J = 8.1 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 21.4, 26.1, 26.2, 26.5 (2C), 31.2, 43.7, 55.0, 70.5, 119.9, 125.65, 125.70, 125.9, 127.3 (2C), 127.8 (2C), 128.2, 128.6, 129.1, 129.5 (2C), 130.5, 132.0, 133.3, 134.1, 135.1, 135.8, 137.3, 137.6, 143.4.

MS (FAB): m/z (%) = 482 (6.8) [M + H⁺], 154 (100).

HRMS–FAB: m/z [M + H]⁺ calcd for C₃₁H₃₂NO₂S: 482.2154; found: 482.2159.

(±)-1-Cyclohexyl-2-methylsulfonyl-2,3-dihydro-1H-benzo[f]isoindole (12g)

Bromoene **11g** (36.8 mg, 0.0897 mmol) was converted to **12g** (13.7 mg, 46% yield) by the reaction for 6 h.

Colorless oil; IR (KBr): 1346 (NSO₂), 1161 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.99–1.33 (m, 6H), 1.61–1.80 (m, 5H), 2.60 (s, 3H, SO₂Me), 4.76 (d, J = 16.2 Hz, 1H, 3-CHH), 4.86 (d, J = 16.2 Hz, 1H, 3-CHH), 4.92 (d, J = 4.5 Hz, 1H, 1-H), 7.48–7.51 (m, 2H, Ar), 7.71 (s, 2H, 4-H and 9-H), 7.82–7.87 (m, 2H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 26.1, 26.17, 26.21, 28.5, 28.6, 34.8, 45.3, 53.8, 70.4, 120.9, 122.3, 126.2, 126.3, 127.8, 128.0, 132.9, 133.2, 135.9, 138.2.

MS (FAB): m/z (%) = 330 (34) [M + H⁺], 246 (100).

HRMS–FAB: m/z [M + H]⁺ calcd for C₁₉H₂₄NO₂S: 330.1528; found: 330.1514.

(±)-9-Butyl-2-(4-methylphenylsulfonyl)-1-pentyl-2,3-dihydro-1H-benzo[f]isoindole (12i)

Bromoene **11i** (72.0 mg, 0.136 mmol) was converted to **12i** (39.9 mg, 65% yield) by the reaction for 3 h.

Colorless oil; IR (KBr): 1346 (NSO₂), 1161 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.82 (t, J = 7.2 Hz, 3H, CMe), 0.97 (t, J = 7.2 Hz, 3H, CMe), 1.15–1.28 (m, 5H), 1.39–1.54 (m, 5H), 1.74–1.85 (m, 1H), 1.98–2.10 (m, 1H), 2.24 (s, 3H, PhMe), 2.88 (dt, J = 13.8, 3.3 Hz, 1H, 1'-CHH), 2.98 (dt, J = 13.8, 3.3 Hz, 1H, 1'-CHH), 4.78 (d, J = 16.5 Hz, 1H, 3-CHH), 4.84 (d, J = 16.5 Hz, 1H, 3-CHH), 5.29 (dd, J = 5.7, 3.3 Hz, 1H, 1-H), 7.09 (d, J = 8.7 Hz, 2H, Ph), 7.39–7.47 (m, 3H, Ar), 7.64 (d, J = 8.7 Hz, 2H, Ph), 7.73 (dd, J = 7.8, 1.8 Hz, 1H, Ar), 7.93 (dd, J = 7.5, 1.8 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 14.0, 14.1, 21.3, 22.5, 23.3, 24.1, 29.2, 31.8, 32.8, 36.4, 53.3, 65.4, 119.1, 123.9, 125.4, 125.5, 127.0 (2C), 128.5, 129.5 (2C), 131.5, 132.5, 133.7, 135.2, 135.6, 137.1, 143.2.

MS (FAB): m/z (%) = 450 (62) [M + H⁺], 378 (100).

HRMS–FAB: m/z [M + H]⁺ calcd for C₂₈H₃₆NO₂S: 450.2467; found: 450.2458.

(±)-2-(4-Methylphenylsulfonyl)-1-pentyl-2,3-dihydro-1H-benzo[f]isoindole (12k)

Bromoene **11k** (94.2 mg, 0.199 mmol) was converted to **12k** (37.8 mg, 48% yield) by the reaction for 1.5 h.

Colorless oil; IR (KBr): 1346 (NSO₂), 1163 cm^{–1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.81 (t, J = 6.9 Hz, 3H, CMe), 1.02–1.10 (m, 1H), 1.18–1.25 (m, 4H), 1.39–1.47 (m, 1H), 1.89–2.00 (m, 1H), 2.13–2.25 (m, 1H), 2.31 (s, 3H, PhMe), 4.77 (d, J = 14.7 Hz, 1H, 3-CHH), 4.83 (d, J = 14.7 Hz, 1H, 3-CHH), 5.16 (t, J = 4.5 Hz, 1H, 1-H), 7.20 (d, J = 8.1 Hz, 2H, Ph), 7.40–7.46 (m, 2H, Ar), 7.53 (s, 1H, Ar), 7.57 (s, 1H, Ar), 7.72 (d, J = 8.1 Hz, 2H, Ph), 7.75–7.79 (m, 2H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 14.0, 21.4, 22.5, 23.2, 31.8, 37.0, 53.4, 65.5, 120.8, 120.9, 125.88, 125.93, 127.3 (2C), 127.67, 127.68, 127.8, 129.7 (2C), 133.0, 134.9, 135.0, 139.3, 143.4.

(1R)-1-Isopropyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzo[f]isoindole (12l)

Bromoene **11l** (52.8 mg, 0.118 mmol) was converted to **12l** (10.5 mg, 24% yield) by the reaction for 4 h.

Colorless oil; $[\alpha]_D^{27}$ –20.8 (c 0.60, CHCl₃).

IR (KBr): 1344 (NSO₂), 1161 cm^{–1} (NSO₂).

¹H NMR (500 MHz, CDCl₃): δ = 0.80 (d, J = 6.7 Hz, 3H, CMe), 0.99 (d, J = 7.3 Hz, 3H, CMe), 2.19 (s, 3H, PhMe), 2.32–2.36 (m, 1H, Me₂CH), 4.71 (s, 1H, J = 15.5 Hz, 3-CHH), 4.74 (d, J = 15.5 Hz, 1H, 3-CHH), 4.99 (d, J = 4.3 Hz, 1H, 1-H), 7.06 (d, J = 7.9 Hz, 2H,

Ph), 7.357 (d, $J = 6.1$ Hz, 1H, Ar), 7.365 (d, $J = 6.1$ Hz, 1H, Ar), 7.47 (s, 1H, Ar), 7.50 (s, 1H, Ar), 7.59 (d, $J = 7.9$ Hz, 2H, Ph), 7.66–7.71 (m, 2H, Ar).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 17.3, 18.4, 21.4, 35.8, 53.8, 70.9, 120.6, 121.9, 125.8, 125.9, 127.1$ (2C), 127.6, 128.0, 129.6 (2C), 132.8, 133.0, 135.3, 135.9, 137.6, 143.3.

MS (FAB): m/z (%) = 366 (22) [$\text{M} + \text{H}^+$], 154 (100).

HRMS–FAB: m/z [$\text{M} + \text{H}^+$] calcd for $\text{C}_{22}\text{H}_{24}\text{NO}_2\text{S}$: 366.1528; found: 366.1523.

(1S)-1-[(1S)-1-[*tert*-Butyl(diphenyl)silyloxy]ethyl]-9-methyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzof[*f*]isoindole (12o)

Bromoene **11o** (57.3 mg, 0.0818 mmol) was converted to **12o** (20.0 mg, 39% yield) by the reaction using $\text{Pd}(\text{OAc})_2$ (0.8 mg, 0.00327 mmol) for 24 h.

Colorless oil; $[\alpha]_D^{23} -86.5$ (c 0.60, CHCl_3).

IR (KBr): 1346 (NSO_2), 1161 cm^{-1} (NSO_2).

^1H NMR (300 MHz, CDCl_3): $\delta = 0.63$ (s, 9H, CMe_3), 1.26 (d, $J = 6.0$ Hz, 3H, CMe), 2.17 (s, 3H, CMe), 2.32 (s, 3H, PhMe), 4.27 (d, $J = 6.0$ Hz, 1H, OCH), 4.81 (d, $J = 15.6$ Hz, 1H, 3-CHH), 5.00 (d, $J = 15.6$ Hz, 1H, 3-CHH), 5.13 (s, 1H, 1-H), 6.99–7.02 (m, 6H, Ar), 7.27–7.58 (m, 11H, Ar), 7.75 (d, $J = 7.5$ Hz, 1H, Ar), 7.90 (d, $J = 8.1$ Hz, 1H, Ar).

^{13}C NMR (68 MHz, CDCl_3): $\delta = 15.5, 18.8, 21.4, 21.6, 26.6$ (3C), 55.0, 70.8, 72.8, 118.7, 123.7, 125.3 (2C), 127.0 (2C), 127.23 (2C), 127.25 (2C), 127.6, 128.2, 129.2 (2C), 129.37, 129.40, 132.1, 132.7, 133.4, 134.1, 135.0, 135.5 (2C), 135.9 (2C), 136.2, 136.8, 143.1.

MS (FAB): m/z (%) = 620 (21) [$\text{M} + \text{H}^+$], 336 (100).

HRMS–FAB: m/z [$\text{M} + \text{H}^+$] calcd for $\text{C}_{38}\text{H}_{42}\text{NO}_3\text{SSi}$: 620.2665; found: 620.2663.

(1R)-9-Butyl-1-cyclohexyl-6-methoxy-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzof[*f*]isoindole (12p)

Bromoene **11p** (60.2 mg, 0.105 mmol) was converted to **12p** (29.4 mg, 57% yield) by the reaction for 5 h.

Colorless oil; $[\alpha]_D^{26} -63.9$ (c 0.82, CHCl_3).

IR (KBr): 1348 (NSO_2), 1163 cm^{-1} (NSO_2).

^1H NMR (300 MHz, CDCl_3): $\delta = 0.97$ (t, $J = 7.2$ Hz, 3H, CMe), 1.11–1.46 (m, 9H), 1.60–1.94 (m, 6H), 2.20 (s, 3H, PhMe), 2.82 (dt, $J = 11.7, 4.8$ Hz, 1H, 1'-CHH), 3.40 (dt, $J = 11.7, 5.1$ Hz, 1H, 1'-CHH), 3.91 (s, 3H, OMe), 4.70 (d, $J = 16.5$ Hz, 1H, NCHH), 4.79 (d, $J = 16.5$ Hz, 1H, NCHH), 5.10 (s, 1H, 1-H), 6.77 (dd, $J = 5.7, 3.3$ Hz, 1H, 7-H), 7.01 (d, $J = 8.4$ Hz, 2H, Ph), 7.26–7.28 (m, 3H, Ar), 7.57 (d, $J = 8.4$ Hz, 2H, Ph).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.2, 21.3, 23.5, 26.2, 26.5, 26.6, 26.7, 31.5, 33.3, 34.5, 45.7, 55.0, 55.2,$

70.8, 105.2, 118.6, 121.3, 123.9, 125.4, 127.2 (2C), 129.4 (2C), 134.1, 135.2, 136.0, 136.4, 137.7, 143.1, 157.7.

MS (FAB): m/z (%) = 492 (38) [$\text{M} + \text{H}^+$], 408 (100).

HRMS–FAB: m/z [$\text{M} + \text{H}^+$] calcd for $\text{C}_{30}\text{H}_{38}\text{NO}_3\text{S}$: 492.2572; found: 492.2575.

(1R)-9-Butyl-1-cyclohexyl-7-methoxy-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzof[*f*]isoindole (12q)

Bromoene **11q** (57.6 mg, 0.101 mmol) was converted to **12q** (18.5 mg, 37% yield) by the reaction for 8 h.

Colorless oil; $[\alpha]_D^{28} -88.2$ (c 0.40, CHCl_3).

IR (KBr): 1344 (NSO_2), 1163 cm^{-1} (NSO_2).

^1H NMR (300 MHz, CDCl_3): $\delta = 1.00$ (t, $J = 6.9$ Hz, 3H, CMe), 1.10–1.92 (m, 15H), 2.19 (s, 3H, PhMe), 2.81–2.95 (m, 2H, 1'-CH₂), 3.91 (s, 3H, OMe), 4.68 (d, $J = 16.2$ Hz, 1H, NCHH), 4.78 (d, $J = 16.2$ Hz, 1H, NCHH), 5.11 (s, 1H, 1-H), 7.01 (d, $J = 8.1$ Hz, 2H, Ph), 7.09 (dd, $J = 9.0, 3.0$ Hz, 1H, 6-H), 7.20 (d, $J = 3.0$ Hz, 1H, 8-H), 7.27 (s, 1H, 4-H), 7.59 (d, $J = 8.1$ Hz, 2H, Ph), 7.61 (d, $J = 9.0$ Hz, 1H, 5-H).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.0, 21.3, 23.3, 26.2, 26.5$ (2C), 26.7, 29.5, 31.6, 32.3, 45.5, 54.8, 55.3, 70.5, 103.1, 117.4, 118.4, 127.2 (2C), 129.0, 129.3 (2C), 129.9, 131.1, 132.6, 133.6, 135.2, 137.4, 143.1, 157.4.

MS (FAB): m/z (%) = 492 (30) [$\text{M} + \text{H}^+$], 408 (100).

HRMS–FAB: m/z [$\text{M} + \text{H}^+$] calcd for $\text{C}_{30}\text{H}_{38}\text{NO}_3\text{S}$: 492.2572; found: 492.2581.

(±)-4-[(Z)-Benzylidene]-2-*tert*-butyl-1-(4-methylphenylsulfonyl)-3-[(Z)-pentylidene]-1H-pyrrole (13j)

Bromoene **11j** (61.3 mg, 0.119 mmol) was converted to **13j** (3.6 mg, 7% yield) by the reaction for 7 h.

Colorless oil; IR (KBr): 1348 (NSO_2), 1163 cm^{-1} (NSO_2).

^1H NMR (500 MHz, CDCl_3): $\delta = 0.93$ (t, $J = 7.5$ Hz, 3H, CMe), 0.97 (s, 9H, CMe_3), 1.25–1.37 (m, 4H), 1.89–2.04 (m, 2H), 2.37 (s, 3H, PhMe), 4.24 (s, 1H, 2-H), 4.35 (dd, $J = 17.1, 1.8$ Hz, 1H, 5-CHH), 4.58 (dd, $J = 17.1, 2.4$ Hz, 1H, 5-CHH), 5.60 (dd, $J = 9.2, 5.5$ Hz, 1H, C=CH), 6.48 (s, 1H, C=CH), 7.19–7.21 (m, 4H, Ph), 7.23 (d, $J = 7.3$ Hz, 1H, Ph), 7.34 (d, $J = 7.3$ Hz, 1H, Ph), 7.36 (d, $J = 7.9$ Hz, 1H, Ph), 7.63 (d, $J = 7.9$ Hz, 2H, Ph).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.1, 21.5, 22.7, 27.3$ (3C), 31.0, 31.7, 38.2, 52.8, 69.6, 118.0, 125.5, 126.9, 127.5 (2C), 128.4 (2C), 128.7 (2C), 129.5 (2C), 135.2, 136.8, 137.4, 138.7, 143.2.

MS (FAB): m/z (%) = 438 (15) [$\text{M} + \text{H}^+$], 154 (100).

HRMS-FAB: m/z $[M + H]^+$ calcd for $C_{27}H_{36}NO_2S$: 438.2467; found: 438.2481.

***N*-(But-2-ynyl)-*N*-(3-phenylprop-2-ynyl)-4-methylbenzenesulfonamide (14m)**

Bromoene **11m** (43.7 mg, 0.105 mmol) was converted to **14m** (19.2 mg, 54% yield) by the reaction for 0.5 h.

Colorless oil; IR (KBr): 2362 (C≡C), 2330 (C≡C), 1352 (NSO₂), 1165 cm⁻¹ (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 1.69 (t, J = 2.4 Hz, 3H, CMe), 2.35 (s, 3H, PhMe), 4.13 (q, J = 2.4 Hz, 2H, NCH₂), 4.38 (s, 2H, NCH₂), 7.16 (dd, J = 6.6, 1.8 Hz, 2H, Ph), 7.23–7.30 (m, 5H, Ph), 7.75 (dd, J = 6.6, 1.8 Hz, 2H, Ph).

¹³C NMR (75 MHz, CDCl₃): δ = 3.46, 21.4, 37.0, 37.1, 71.6, 81.6, 81.9, 85.6, 122.2, 128.0 (2C), 128.1 (2C), 128.4, 129.4 (2C), 131.6 (2C), 135.4, 143.6.

(±)-*N*-(1-Cyclohexylhept-2-ynyl)-*N*-(3-phenylprop-2-ynyl)amine (14n)

Bromoene **11n** (59.2 mg, 0.152 mmol) was converted to **14n** (12.0 mg, 26% yield) by the reaction for 2.5 h.

Colorless oil; IR (KBr): 3317 (NH), 2237 cm⁻¹ (C≡C).

¹H NMR (300 MHz, CDCl₃): δ = 0.92 (t, J = 7.5 Hz, 3H, CMe), 1.13–1.55 (m, 10H), 1.65–1.85 (m, 5H), 2.22 (td, J = 6.9, 1.8 Hz, 2H, CH₂C≡C), 3.42 (dt, J = 5.1, 1.8 Hz, 1H, NCH), 3.68 (d, J = 16.8 Hz, 1H, NCHH), 3.84 (d, J = 16.8 Hz, 1H, NCHH), 7.28–7.30 (m, 3H, Ph), 7.39–7.44 (m, 2H, Ph).

¹³C NMR (75 MHz, CDCl₃): δ = 13.6, 18.4, 22.0, 26.1, 26.2, 26.5, 28.4, 30.2, 31.1, 37.2, 42.5, 55.0, 79.2, 83.1, 85.1, 87.7, 123.3, 127.9, 128.2 (2C), 131.7 (2C).

(5*R*)-4-Butyl-5-cyclohexyl-6-(4-methylphenylsulfonyl)-6,7-dihydro-5*H*-furo[2,3-*f*]isoindole (16a)

Bromoene **15a** (58.2 mg, 0.109 mmol) was converted to **16a** (21.3 mg, 43% yield) by the reaction for 2 h.

Colorless oil; $[\alpha]_D^{29}$ –67.2 (c 1.02, CHCl₃).

IR (KBr): 1344 (NSO₂), 1163 cm⁻¹ (NSO₂).

¹H NMR (270 MHz, CDCl₃): δ = 0.94 (t, J = 7.3 Hz, 3H, CMe), 1.00–1.89 (m, 16H), 2.23 (s, 3H, PhMe), 2.71 (t, J = 6.8 Hz, 2H, 1'-CH₂), 4.63 (d, J = 15.9 Hz, 1H, 7-CHH), 4.72 (d, J = 15.9 Hz, 1H, 7-CHH), 5.02 (s, 1H, 5-H), 6.68 (d, J = 2.2 Hz, 1H, 2-H), 6.97 (s, 1H, 8-H), 7.03 (d, J = 8.4 Hz, 2H, Ph), 7.52 (d, J = 2.2 Hz, 1H, 3-H), 7.56 (d, J = 8.4 Hz, 2H, Ph).

¹³C NMR (68 MHz, CDCl₃): δ = 14.1, 21.4, 23.0, 26.3, 26.5, 26.6, 26.8, 30.5, 31.6, 32.7, 45.6, 55.1, 70.0, 102.4, 105.3, 126.7, 127.1 (2C), 129.2 (2C), 129.5, 132.7, 134.5, 135.1, 143.0, 144.5, 154.7.

MS (FAB): m/z (%) = 452 (45) $[M + H]^+$, 368 (100).

HRMS-FAB: m/z $[M + H]^+$ calcd for $C_{27}H_{34}NO_3S$: 452.2259; found: 452.2258.

(5*R*)-4-Butyl-5-cyclohexyl-1,6-bis(4-methylphenylsulfonyl)-1,5,6,7-tetrahydropyrrolo[3,4-*f*]indole (16b)

Bromoene **15b** (111 mg, 0.162 mmol) was converted to **16b** (73.3 mg, 75%) by the reaction using Pd(OAc)₂ (7.7 mg, 0.0346 mmol) in DMF at 120 °C for 2 h.

Colorless oil; $[\alpha]_D^{26}$ +79.7 (c 0.98, CHCl₃).

IR (KBr): 1597 (NC=C), 1360 (NSO₂), 1346 (NSO₂), 1178 (NSO₂), 1161 cm⁻¹ (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.92 (t, J = 7.1 Hz, 3H, CMe), 1.01–1.37 (m, 8H), 1.61–1.85 (m, 7H), 2.20 (s, 3H, PhMe), 2.38 (s, 3H, PhMe), 2.61–2.67 (m, 2H, 1'-CH₂), 4.63 (d, J = 15.9 Hz, 1H, 7-CHH), 4.76 (d, J = 15.9 Hz, 1H, 7-CHH), 4.97 (s, 1H, 5-H), 6.57 (dd, J = 3.8, 0.7 Hz, 1H, 3-H), 6.97 (d, J = 7.9 Hz, 2H, Ph), 7.25 (d, J = 7.9 Hz, 2H, Ph), 7.46 (d, J = 3.8 Hz, 1H, 2-H), 7.48 (s, 1H, 8-H), 7.53 (ddd, J = 7.9, 1.8, 1.8 Hz, 2H, Ph), 7.73 (ddd, J = 7.9, 1.8, 1.8 Hz, 2H, Ph).

¹³C NMR (126 MHz, CDCl₃): δ = 14.0, 21.3, 21.6, 22.9, 26.2, 26.4, 26.5, 26.7, 30.1, 31.5, 32.6, 45.4, 55.2, 69.9, 104.5, 107.2, 125.8, 126.8 (2C), 127.2 (2C), 129.3 (3C), 129.6, 129.9, 130.0, 133.5, 134.7, 135.1, 135.2, 135.4, 143.0, 145.0.

MS (FAB): m/z (%) = 605 (5.2) $[M + H]^+$, 521 (100).

HRMS-FAB: m/z $[M + H]^+$ calcd for $C_{34}H_{41}N_2O_4S_2$: 605.2508; found: 605.2493.

(5*R*)-4-Butyl-5-cyclohexyl-1-(2,4,6-trimethylphenylsulfonyl)-6-(4-methylphenylsulfonyl)-1,5,6,7-tetrahydropyrrolo[3,4-*f*]indole (16c)

Bromoene **15c** (72.0 mg, 0.101 mmol) was converted to **16c** (51.4 mg, 81%) by the reaction using Pd(OAc)₂ (4.5 mg, 0.0202 mmol) in DMF at 120 °C for 2 h.

Colorless oil; $[\alpha]_D^{26}$ +52.2 (c 1.645, CHCl₃).

IR (KBr): 1603 (NC=C), 1350 (NSO₂), 1161 cm⁻¹ (NSO₂).

¹H NMR (270 MHz, CDCl₃): δ = 0.86 (t, J = 6.9 Hz, 3H, CMe), 0.91–1.34 (m, 8H), 1.40–1.86 (m, 7H), 2.23 (s, 3H, PhMe), 2.32 (s, 3H, PhMe), 2.46 (s, 6H, PhMe), 2.68 (t, J = 6.6 Hz, 2H, 1'-CH₂), 4.54 (d, J = 16.0 Hz, 1H, 7-CHH), 4.66 (d, J = 16.0 Hz, 1H, 7-CHH), 4.96 (s, 1H, 5-H), 6.53 (d, J = 3.7 Hz, 1H, 3-H), 6.94–6.99 (m, 5H, Ar), 7.39 (d, J = 3.7 Hz, 1H, 2-H), 7.50 (d, J = 8.1 Hz, 2H, Ph).

¹³C NMR (126 MHz, CDCl₃): δ = 14.0, 21.0, 21.3, 22.5 (2C), 22.9, 26.2, 26.5, 26.7, 30.1, 31.5, 32.7, 45.3, 55.2, 69.9, 103.7, 105.2 (2C), 125.9, 127.2 (2C),

129.2 (3C), 129.3, 129.6, 132.3 (3C), 132.9, 134.6, 134.7, 135.1, 140.1, 143.0, 144.1.

MS (FAB): m/z (%) = 633 (28) $[M + H]^+$, 549 (100).

HRMS–FAB: m/z $[M + H]^+$ calcd for $C_{36}H_{45}N_2O_4S_2$: 633.2821; found: 633.2795.

(5R)-4-Butyl-5-cyclohexyl-N,N-dimethyl-6-(4-methylphenylsulfonyl)-6,7-dihydropyrrolo[3,4-f]indole-1(5H)-sulfonamide (16d)

Bromoene **15d** (49.7 mg, 0.0778 mmol) was converted to **16d** (22.7 mg, 52%) by the reaction using $Pd(OAc)_2$ (1.8 mg, 0.00802 mmol) for 12 h.

Pale orange oil; $[\alpha]_D^{25} +37.8$ (c 0.740, $CHCl_3$).

IR (KBr): 1599 (NC=C), 1387 (NSO₂), 1344 (NSO₂), 1159 cm^{-1} (NSO₂).

¹H NMR (300 MHz, $CDCl_3$): δ = 0.96 (t, J = 7.1 Hz, 3H, CMe), 1.03–1.54 (m, 9H), 1.61–1.94 (m, 6H), 2.23 (s, 3H, PhMe), 2.71–2.79 (m, 2H, 1'-CH₂), 2.785 (s, 3H, NMe), 2.787 (s, 3H, NMe), 4.63 (d, J = 16.0 Hz, 1H, 7-CHH), 4.73 (d, J = 16.0 Hz, 1H, 7-CHH), 5.07 (s, 1H, 5-H), 6.57 (d, J = 3.7 Hz, 1H, 3-H), 7.04 (d, J = 8.3 Hz, 2H, Ph), 7.36 (d, J = 3.7 Hz, 1H, 2-H), 7.42 (s, 1H, 8-H), 7.57 (d, J = 8.3 Hz, 2H, Ph).

¹³C NMR (75 MHz, $CDCl_3$): δ = 14.0, 21.3, 22.9, 26.2, 26.4, 26.5, 26.7, 30.1, 31.5, 32.6, 38.4 (2C), 45.4, 55.1, 70.0, 104.6, 105.1, 126.6, 127.2 (2C), 129.2, 129.26 (2C), 129.29, 132.9, 134.6, 135.1, 135.3, 143.0.

MS (FAB): m/z (%) = 558 (37) $[M + H]^+$, 474 (100).

HRMS–FAB: m/z $[M + H]^+$ calcd for $C_{29}H_{40}N_3O_4S_2$: 558.2460; found: 558.2483.

(7R)-8-Butyl-7-cyclohexyl-1,6-bis(4-methylphenylsulfonyl)-1,5,6,7-tetrahydropyrrolo[3,4-f]indole (16e)

Bromoene **15e** (53.5 mg, 0.0780 mmol) was converted to **16e** (20.0 mg, 42%) by the reaction using $Pd(OAc)_2$ (3.5 mg, 0.0156 mmol) in DMF at 120 °C for 4 h.

Colorless oil; $[\alpha]_D^{26} -349.8$ (c 0.86, $CHCl_3$).

IR (KBr): 1597 (NC=C), 1369 (NSO₂), 1344 (NSO₂), 1174 (NSO₂), 1161 cm^{-1} (NSO₂).

¹H NMR (300 MHz, $CDCl_3$): δ = 0.83–1.47 (m, 11H), 1.51–1.62 (m, 5H), 1.79–1.85 (m, 2H), 2.25 (s, 3H, PhMe), 2.30 (s, 3H, PhMe), 2.38–2.53 (m, 1H, 1'-CHH), 3.49–3.59 (m, 1H, 1'-CHH), 4.54 (d, J = 15.9 Hz, 1H, 5-CHH), 4.69 (dd, J = 15.9, 0.6 Hz, 1H, 5-CHH), 4.95 (s, 1H, 7-H), 6.52 (d, J = 3.8 Hz, 1H, 3-H), 6.91 (s, 1H, 4-H), 7.04 (d, J = 8.1 Hz, 2H, Ph), 7.08 (d, J = 8.1 Hz, 2H, Ph), 7.37 (ddd, J = 8.1, 1.9, 1.9 Hz, 2H, Ph), 7.56 (ddd, J = 8.1, 1.9, 1.9 Hz, 2H, Ph), 7.59 (d, J = 3.8 Hz, 1H, 2-H).

¹³C NMR (126 MHz, $CDCl_3$): δ = 14.0, 21.4, 21.5, 22.9, 26.2, 26.6 (2C), 26.7, 30.6, 31.0, 32.1, 45.7, 55.0, 70.5, 111.1, 111.9, 126.48, 126.49 (2C), 127.2 (2C),

129.3 (2C), 129.4 (2C), 132.1, 133.9, 134.2, 134.4, 135.1, 135.3, 137.2, 143.2, 144.6.

MS (FAB): m/z (%) = 605 (31) $[M + H]^+$, 521 (100).

HRMS–FAB: m/z $[M + H]^+$ calcd for $C_{34}H_{41}N_2O_4S_2$: 605.2508; found: 605.2531.

(3R)-4-Butyl-3-cyclohexyl-2,5-bis(4-methylphenylsulfonyl)-1,2,3,5-tetrahydropyrrolo[3,4-b]carbazole (18a)

Bromoene **17a** (74.0 mg, 0.101 mmol) was converted to **18a** (33.8 mg, 51% yield) by the reaction using $Pd(OAc)_2$ (2.3 mg, 0.0101 mmol) in DMF at 120 °C for 18 h.

Colorless oil; $[\alpha]_D^{26} -122$ (c 0.30, $CHCl_3$).

IR (KBr): 1597 (C=CN), 1367 (NSO₂), 1346 (NSO₂), 1173 (NSO₂), 1163 cm^{-1} (NSO₂).

¹H NMR (300 MHz, $CDCl_3$): δ = 0.88 (t, J = 7.2 Hz, 3H, CMe), 1.11–1.30 (m, 9H), 1.53–1.93 (m, 6H), 2.17 (s, 3H, PhMe), 2.22 (s, 3H, PhMe), 2.63–2.73 (m, 1H, 1'-CHH), 3.84–3.94 (m, 1H, 1'-CHH), 4.61 (d, J = 16.5 Hz, 1H, 1-CHH), 4.76 (d, J = 16.5 Hz, 1H, 1-CHH), 5.07 (s, 1H, 3-H), 6.72 (d, J = 8.4 Hz, 2H, Ph), 6.78 (d, J = 8.4 Hz, 2H, Ph), 7.06 (d, J = 8.1 Hz, 2H, Ph), 7.12 (s, 1H, 10-H), 7.25–7.30 (m, 1H, Ar), 7.40 (dd, J = 7.5, 7.5, 1.5 Hz, 1H, Ar), 7.47 (dd, J = 7.5, 0.6 Hz, 1H, Ar), 7.61 (d, J = 8.4 Hz, 2H, Ph), 8.16 (d, J = 7.5 Hz, 1H, Ar).

¹³C NMR (75 MHz, $CDCl_3$): δ = 14.0, 21.4, 21.5, 22.9, 26.3, 26.5, 26.6, 26.7, 31.0, 31.15, 31.20, 45.9, 55.3, 71.0, 110.4, 119.2, 120.6, 125.8, 127.0 (2C), 127.1, 127.3 (2C), 128.3 (2C), 129.5 (2C), 130.0, 131.08, 131.13, 131.9, 135.0, 135.8, 140.17, 140.24, 142.5, 143.4, 144.3.

MS (FAB): m/z (%) = 655 (10) $[M + H]^+$, 154 (100).

HRMS–FAB: m/z $[M + H]^+$ calcd for $C_{38}H_{43}N_2O_4S_2$: 655.2664; found: 655.2661.

(3R)-4-Butyl-3-cyclohexyl-2-(4-methylphenylsulfonyl)-5-(2,4,6-trimethylphenylsulfonyl)-1,2,3,5-tetrahydropyrrolo[3,4-b]carbazole (18b)

Bromoene **17b** (53.1 mg, 0.0695 mmol) was converted to **18b** (14.9 mg, 31%) by the reaction using $Pd(OAc)_2$ (0.8 mg, 0.00356 mmol) in DMF at 120 °C for 3 h.

Pale yellow oil; $[\alpha]_D^{26} -107.6$ (c 0.690, $CHCl_3$).

IR (KBr): 1601 (NC=C), 1346 (NSO₂), 1162 cm^{-1} (NSO₂).

¹H NMR (300 MHz, $CDCl_3$): δ = 0.92 (t, J = 7.1 Hz, 3H, CMe), 1.01–1.37 (m, 8H), 1.61–1.85 (m, 7H), 2.11 (s, 6H, PhMe), 2.20 (s, 3H, PhMe), 2.38 (s, 3H, PhMe), 2.64 (dt, J = 14.6, 5.0 Hz, 1H, 1'-CHH), 3.55 (dt, J = 14.6, 5.0 Hz, 1H, 1'-CHH), 4.67 (d, J = 15.6 Hz, 1H, 1-CHH), 4.80 (d, J = 15.6 Hz, 1H, 1-CHH), 5.01 (s, 1H, 3-H), 6.67 (s, 2H, Ph), 7.03 (d, J = 7.9 Hz,

2H, Ph), 7.15–7.20 (m, 2H, Ar), 7.35 (s, 1H, 10-H), 7.56–7.59 (m, 1H, Ar), 7.58 (d, $J = 7.9$ Hz, 2H, Ph), 7.66–7.67 (m, 1H, Ar).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 14.0, 20.9, 21.4, 22.5$ (2C), 22.9, 26.2, 26.4, 26.6, 26.8, 31.1, 31.2, 31.4, 45.6, 55.3, 71.0, 110.4, 116.7, 119.4 (2C), 124.1, 126.5, 127.1, 127.2 (2C), 128.7, 129.1, 129.5 (2C), 131.8 (2C), 134.1, 134.6, 135.0, 139.9 (2C), 140.1, 141.1, 143.1, 143.3.

MS (FAB): m/z (%) = 683 (16) $[\text{M} + \text{H}^+]$, 154 (100).

HRMS–FAB: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{40}\text{H}_{47}\text{N}_2\text{O}_4\text{S}_2$: 638.2977; found: 638.2974.

(3R)-4-Butyl-3-cyclohexyl-5-methyl-2-(4-methylphenylsulfonyl)-1,2,3,5-tetrahydropyrrolo[3,4-*b*]carbazole (18d)

Bromoene **17d** (118 mg, 0.20 mmol) was converted to **18d** (43.7 mg, 43%) by the reaction using $\text{Pd}(\text{OAc})_2$ (4.5 mg, 0.0198 mmol) for 36 h.

Pale yellow oil; $[\alpha]_D^{27} +10.2$ (c 1.28, CHCl_3).

IR (KBr): 1601 (NC=C), 1342 (NSO₂), 1161 (NSO₂), 1092 cm^{-1} (NC).

^1H NMR (300 MHz, CDCl_3): $\delta = 0.96$ –1.00 (m, 4H), 1.04–1.48 (m, 8H), 1.60–1.64 (m, 2H), 1.77–1.92 (m, 4H), 2.19 (s, 3H, PhMe), 2.73–2.82 (m, 1H, 1'-CHH), 3.12–3.19 (m, 1H, 1'-CHH), 3.98 (s, 3H, NMe), 4.74 (d, 1H, $J = 15.4$ Hz, 1-CHH), 4.83 (d, 1H, $J = 15.4$ Hz, 1-CHH), 5.06 (s, 1H, 3-H), 7.01 (d, $J = 7.9$ Hz, 2H, Ph), 7.18 (dd, $J = 8.0, 8.0$ Hz, 1H, Ar), 7.34 (d, $J = 8.0$ Hz, 1H, Ar), 7.43 (dd, $J = 8.0, 8.0$ Hz, 1H, Ar), 7.58 (s, 1H, 10-H), 7.58 (d, $J = 7.9$ Hz, 2H, Ph), 7.94 (d, $J = 8.0$ Hz, 1H, Ar).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.8, 22.1, 23.6, 27.0, 27.2, 27.3, 27.5, 29.9, 32.3, 32.8, 34.9, 46.7, 56.0, 71.5, 109.5, 111.6, 119.8, 120.3, 120.8, 123.2, 125.1, 126.5, 127.9$ (2C), 129.6, 130.1 (2C), 136.0, 138.4, 139.8, 143.1, 143.8.

MS (FAB): m/z (%) = 515 (21) $[\text{M} + \text{H}^+]$, 431 (100).

HRMS–FAB: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{39}\text{N}_2\text{O}_2\text{S}$: 515.2737; found: 515.2747.

(3R)-4-Butyl-3-cyclohexyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzo[4,5]thieno[2,3-*f*]isoindole (18e)

Bromoene **17e** (70.4 mg, 0.118 mmol) was converted to **18e** (29.7 mg, 49% yield) by the reaction for 3 h.

Colorless oil; $[\alpha]_D^{25} +27.8$ (c 0.40, CHCl_3).

IR (KBr): 1344 (NSO₂), 1161 cm^{-1} (NSO₂).

^1H NMR (300 MHz, CDCl_3): $\delta = 0.99$ (t, $J = 7.2$ Hz, 3H, CMe), 1.05–1.92 (m, 15H), 2.20 (s, 3H, PhMe), 2.72–2.86 (m, 2H, 1'-CH₂), 4.72 (d, $J = 15.9$ Hz, 1H, 1-CHH), 4.83 (d, $J = 15.9$ Hz, 1H, 1-CHH), 5.09 (s, 1H, 3-H), 7.03 (d, $J = 8.1$ Hz, 2H, Ph), 7.40–7.43 (m,

2H, Ar), 7.59 (d, $J = 8.1$ Hz, 2H, Ph), 7.65 (s, 1H, Ar), 7.79–7.83 (m, 1H, Ar), 8.00–8.03 (m, 1H, Ar).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.0, 21.3, 23.0, 26.2, 26.4, 26.5, 26.7, 30.7, 31.6, 32.2, 45.4, 55.1, 70.4, 112.3, 121.4, 122.8, 124.4, 126.7, 127.2$ (2C), 129.4 (2C), 131.2, 135.0, 135.3, 135.5, 135.6, 137.3, 139.1, 139.3, 143.3.

MS (FAB): m/z (%) = 518 (23) $[\text{M} + \text{H}^+]$, 154 (100).

HRMS–FAB: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{36}\text{NO}_2\text{S}_2$: 518.2187; found: 518.2188.

(3R)-4-Butyl-3-cyclohexyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-benzofuro[2,3-*f*]isoindole (18f)

Bromoene **17f** (62.0 mg, 0.106 mmol) was converted to **18f** (31.4 mg, 59% yield) by the reaction for 1 h.

Colorless oil; $[\alpha]_D^{26} -119$ (c 0.35, CHCl_3).

IR (KBr): 1346 (NSO₂), 1163 cm^{-1} (NSO₂).

^1H NMR (300 MHz, CDCl_3): $\delta = 1.00$ (t, $J = 6.9$ Hz, 3H, CMe), 1.15–1.93 (m, 15H), 2.19 (s, 3H, PhMe), 2.89 (dt, $J = 14.1, 6.3$ Hz, 1H, 1'-CHH), 3.04 (dt, $J = 9.0, 5.4$ Hz, 1H, 1'-CHH), 4.69 (d, $J = 16.5$ Hz, 1H, 1-CHH), 4.80 (d, $J = 16.5$ Hz, 1H, 1-CHH), 5.09 (s, 1H, 3-H), 7.03 (d, $J = 8.1$ Hz, 2H, Ph), 7.06 (s, 1H, Ar), 7.33 (ddd, $J = 7.5, 7.5, 0.9$ Hz, 1H, Ar), 7.42 (ddd, $J = 7.5, 7.5, 0.9$ Hz, 1H, Ar), 7.52 (d, $J = 7.5$ Hz, 1H, Ar), 7.59 (d, $J = 8.1$ Hz, 2H, Ph), 7.84 (d, $J = 7.5$ Hz, 1H, Ar).

^{13}C NMR (75 MHz, CDCl_3): $\delta = 14.0, 21.3, 23.2, 26.2, 26.4, 26.5, 26.7, 30.6, 31.6$ (2C), 45.7, 55.4, 70.1, 102.7, 111.6, 122.1, 122.2, 122.8, 123.9, 126.5, 127.2 (2C), 129.4 (2C), 132.5, 133.1, 135.1, 137.3, 143.2, 156.3, 156.4.

MS (FAB): m/z (%) = 502 (36) $[\text{M} + \text{H}^+]$, 418 (100).

HRMS–FAB: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{36}\text{NO}_3\text{S}$: 502.2416; found: 502.2409.

(1R)-11-Butyl-1-cyclohexyl-2-(4-methylphenylsulfonyl)-2,3-dihydro-1H-naphtho[2,3-*f*]isoindole (18g)

Bromoene **17g** (132 mg, 0.22 mmol) was converted to **18g** (48.7 mg, 43%) by the reaction using $\text{Pd}(\text{OAc})_2$ (1.0 mg, 0.0044 mmol) in DMF at 120 °C for 2 h and a further 3 h with additional $\text{Pd}(\text{OAc})_2$ (1.5 mg, 0.0066 mmol).

Colorless oil; $[\alpha]_D^{26} -165.5$ (c 0.63, CHCl_3).

IR (KBr): 1344 (NSO₂), 1161 cm^{-1} (NSO₂).

^1H NMR (300 MHz, CDCl_3): $\delta = 0.95$ –1.02 (m, 4H), 1.11–1.61 (m, 10H), 1.79–1.97 (m, 4H), 2.16 (s, 3H, PhMe), 3.09 (td, $J = 12.7, 4.6$ Hz, 1H, 1'-CHH), 3.58 (td, $J = 12.7, 4.6$ Hz, 1H, 1'-CHH), 4.78 (d, $J = 16.2$ Hz, 1H, 3-CHH), 4.90 (d, $J = 16.2$ Hz, 1H, 3-CHH), 5.20 (s, 1H, 1-H), 7.00 (d, $J = 8.1$ Hz, 2H, Ph), 7.41 (s,

¹H, Ar), 7.54–7.64 (m, 6H, Ar), 7.86 (dd, *J* = 6.8, 2.2 Hz, 1H, Ar), 8.74 (d, *J* = 7.8 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 13.9, 21.3, 23.1, 26.2, 26.5, 26.7 (2C), 31.1, 31.5, 33.9, 45.6, 55.3, 71.4, 120.1, 125.8, 125.9, 126.7, 127.2 (3C), 128.0, 128.9, 129.0, 129.4 (2C), 131.1, 133.3, 134.1, 134.6, 135.1, 135.9, 139.8, 143.2.

MS (FAB): *m/z* (%) = 512 (49) [M + H⁺], 428 (100).

HRMS–FAB: *m/z* [M + H]⁺ calcd for C₃₃H₃₈NO₂S: 512.2623; found: 512.2661.

Diethyl 9-Butyl-1-pentyl-2,3-dihydro-1*H*-cyclopenta[*b*]naphthalene-2,2-dicarboxylate (20a)

Bromoene **19a** (48.8 mg, 0.0993 mmol) was converted to **20a** (28.1 mg, 68%) by the reaction using Pd(OAc)₂ (1.1 mg, 0.0050 mmol) for 2 h.

Colorless oil; IR (KBr): 1733 cm^{−1} (C=O).

¹H NMR (300 MHz, CDCl₃): δ = 0.82 (t, *J* = 6.7 Hz, 3H, CMe), 1.02 (t, *J* = 7.1 Hz, 3H, CMe), 1.13–1.82 (m, 18H), 2.93–3.02 (m, 1H, 1'-CHH), 3.07–3.17 (m, 1H, 1'-CHH), 3.45 (d, *J* = 16.7 Hz, 1H, 3-CHH), 3.96–4.37 (m, 6H, 2 × OCH₂, 1-H, and 3-CHH), 7.37 (ddd, *J* = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.42 (ddd, *J* = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.47 (s, 1H, 4-H), 7.73 (d, *J* = 8.0 Hz, 1H, Ar), 7.97 (d, *J* = 8.0 Hz, 1H, Ar).

¹³C NMR (75 MHz, CDCl₃): δ = 13.9, 14.0 (2C), 14.1, 22.5, 23.5, 26.9, 29.5, 31.8, 32.3, 32.8, 38.8, 48.2, 61.45, 61.50, 65.4, 121.1, 123.9, 124.8, 124.9, 128.3, 131.6, 133.6, 133.7, 137.4, 142.3, 170.0, 171.6.

MS (FAB): *m/z* (%) = 461 (8.2) [M + Na⁺], 438 (100).

HRMS–FAB: *m/z* [M + Na]⁺ calcd for C₂₈H₃₈NaO₄: 461.2668; found: 461.2650.

Diethyl 4-Butyl-1-(4-methylphenylsulfonyl)-5-pentyl-5,7-dihydrocyclopenta[*f*]indole-6,6-(1*H*)-dicarboxylate (20b)

Bromoene **19b** (104 mg, 0.157 mmol) was converted to **20b** (31.9 mg, 35%) by the reaction using Pd(OAc)₂ (1.8 mg, 0.00786 mmol) in DMF at 120 °C for 24 h.

Colorless oil; IR (KBr): 1732 (C=O), 1597 (NC=C), 1373 (NSO₂), 1176 cm^{−1} (NSO₂).

¹H NMR (300 MHz, CDCl₃): δ = 0.80 (t, *J* = 7.0 Hz, 3H, CMe), 0.95 (t, *J* = 7.0 Hz, 3H, CMe), 1.13–1.73 (m, 18H), 2.36 (s, 3H, PhMe), 2.76 (t, *J* = 7.9 Hz, 2H, 1'-CH₂), 3.37 (d, *J* = 16.7 Hz, 1H, 7-CHH), 3.91–4.37 (m, 6H, 2 × OCH₂, 5-H, and 7-CHH), 6.61 (d, *J* = 3.8 Hz, 1H, 3-H), 7.24 (d, *J* = 8.3 Hz, 2H, Ph), 7.46 (d, *J* = 3.8 Hz, 1H, 2-H), 7.58 (s, 1H, 8-H), 7.77 (d, *J* = 8.3 Hz, 2H, Ph).

¹³C NMR (75 MHz, CDCl₃): δ = 13.9, 13.96, 13.99, 14.1, 21.6, 22.4, 23.3, 26.8, 30.2, 31.8, 32.3, 32.7, 39.0, 47.4, 61.4, 61.5, 65.6, 107.0, 107.4, 125.0, 126.9 (2C), 129.5, 129.9 (2C), 130.9, 134.4, 135.5, 136.3, 138.9, 144.7, 170.0, 171.7.

MS (FAB): *m/z* (%) = 604 (100) [M + Na⁺], 604 (100).

HRMS–FAB: *m/z* [M + Na]⁺ calcd for C₃₃H₄₃NNaO₆S: 604.2709; found: 604.2724.

Supporting Information for this article, including experimental procedures and full characterization for the substrates and their synthetic intermediates, is available online at <http://www.thieme-connect.de/ejournals/toc/synthesis>.

Acknowledgment

This work was supported in part by a Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Organic Synthesis" (H.O.) and for Scientific Research (B) (T.T.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- (1) For recent reviews on cascade reactions, see: (a) Tietze, L. F. *Chem. Rev.* **1996**, *96*, 115–136. (b) Nicolaou, K. C.; Montagnon, T.; Snyder, S. A. *Chem. Commun.* **2003**, 551–564. (c) Wasilke, J.-C.; Obrey, S. J.; Baker, T.; Bazan, G. C. *Chem. Rev.* **2005**, *105*, 1001–1020. (d) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. *Angew. Chem., Int. Ed.* **2006**, *45*, 7134–7186. (e) Kirsch, S. F. *Synthesis* **2008**, 3183–3204. (f) Nicolaou, K. C.; Chen, J. S. *Chem. Soc. Rev.* **2009**, *38*, 2993–3009. (g) Grondal, C.; Jeanty, M.; Enders, D. *Nat. Chem.* **2010**, *2*, 167–178. (h) Vlaar, T.; Ruijter, E.; Orru, R. V. A. *Adv. Synth. Catal.* **2011**, *353*, 809–841.
- (2) Trost, B. M. *Acc. Chem. Res.* **2002**, *35*, 695–705.
- (3) For recent reviews on C–H activation, see: (a) Thansandote, P.; Lautens, M. *Chem. Eur. J.* **2009**, *15*, 5874–5883. (b) Zhang, M. *Adv. Synth. Catal.* **2009**, *351*, 2243–2270. (c) Ackermann, L.; Vicente, R.; Kapdi, A. R. *Angew. Chem., Int. Ed.* **2009**, *48*, 9792–9826. (d) Jazzar, R.; Hitce, J.; Renaudat, A.; Sofack-Kreutzer, J.; Baudoin, O. *Chem. Eur. J.* **2010**, *16*, 2654–2672. (e) Bellina, F.; Rossi, R. *Chem. Rev.* **2010**, *110*, 1082–1146. (f) Yeung, C. S.; Dong, V. M. *Chem. Rev.* **2011**, *111*, 1215–1292.
- (4) For reactions including alkene insertion and C–H activation, see: (a) Blaszykowski, C.; Aktoudianakis, E.; Bressy, C.; Alberico, D.; Lautens, M. *Org. Lett.* **2006**, *8*, 2043–2045. (b) Alonso, I.; Alcamí, M.; Mauleón, P.; Carretero, J. C. *Chem. Eur. J.* **2006**, *12*, 4576–4583. (c) Ruck, R. T.; Huffman, M. A.; Kim, M. M.; Shevlin, M.; Kandur, W. V.; Davies, I. W. *Angew. Chem., Int. Ed.* **2008**, *48*, 4711–4714. (d) Candito, D. A.; Lautens, M. *Angew. Chem., Int. Ed.* **2009**, *48*, 6713–6716.
- (5) For recent examples of palladium-catalyzed cascade reactions including C–H activation, see: (a) Zhao, J.; Yue, D.; Campo, M. A.; Larock, R. C. *J. Am. Chem. Soc.* **2007**, *129*, 5288–5295. (b) Guo, L.-N.; Duan, X.-H.; Liu, X.-Y.; Hu, J.; Bi, H.-P.; Liang, Y. M. *Org. Lett.* **2007**, *9*, 5425–5428. (c) Candito, D. A.; Lautens, M. *Angew. Chem., Int. Ed.* **2009**, *48*, 6713–6716. (d) Wang, G.-W.; Yuan, T.-T.; Li, D.-D. *Angew. Chem., Int. Ed.* **2011**, *50*, 1380–1383.
- (6) For reactions including alkyne insertion and C–H activation, see: (a) Pinto, A.; Neuville, L.; Retailleau, P.; Zhu, J. *Org. Lett.* **2006**, *8*, 4927–4930. (b) Pinto, A.; Neuville, L.; Zhu, J. *Angew. Chem., Int. Ed.* **2007**, *46*, 3291–3295. (c) Chernyak, N.; Gevorgyan, V. *J. Am. Chem. Soc.* **2008**, *130*, 5636–5637. (d) Liu, R.; Zhang, J. *Adv. Synth. Catal.* **2011**, *353*, 36–40. For intermolecular

- reactions with an alkyne followed by C-H activation, see: (e) Larock, R. C.; Doty, M. J.; Tian, Q.; Zenner, J. M. *J. Org. Chem.* **1997**, *62*, 7536–7537. (f) Dong, C.-G.; Yeung, P.; Hu, Q.-S. *Org. Lett.* **2007**, *9*, 363–366.
- (7) For reactions using aryl or alkenyl bromides bearing an alkyne moiety, see: (a) Rahman, S. M. A.; Sonoda, M.; Itahashi, K.; Tobe, Y. *Org. Lett.* **2003**, *5*, 3411–3414. (b) Rahman, S. M. A.; Sonoda, M.; Ono, M.; Miki, K.; Tobe, Y. *Org. Lett.* **2006**, *8*, 1197–1200. (c) Tietze, L. F.; Lotz, F. *Eur. J. Org. Chem.* **2006**, 4676–4684. (d) Tokan, W. M.; Schweizer, S.; Thies, C.; Meyer, F. E.; Parsons, P. J.; de Meijere, A. *Helv. Chim. Acta* **2009**, *92*, 1729–1740.
- (8) A portion of this study (Table 1; Table 2: entries 2, 3, 6, 11, 12; Table 4: entries 1 and 7) has already been reported in a preliminary communication: Ohno, H.; Yamamoto, M.; Iuchi, M.; Tanaka, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 5103–5106.
- (9) (a) Frantz, D. E.; Fässler, R.; Carreira, E. M. *J. Am. Chem. Soc.* **2000**, *122*, 1806–1807. (b) Boyall, D.; López, F.; Sasaki, H.; Frantz, D.; Carreira, E. M. *Org. Lett.* **2000**, *2*, 4233–4236.
- (10) Oh, C. H.; Lim, Y. M. *Tetrahedron Lett.* **2003**, *44*, 267–270.
- (11) For example, the reaction of **11b** with Pd(OAc)₂ (2 mol %) using K₂CO₃ (2 equiv) as the base stereoselectively gave the monocyclic product **13b** in 94% yield.

- (12) A similar result was obtained with malonate congener **19c**, which produced diyne **21** in 69% yield.

- (13) For recent reviews on palladium-catalyzed direct arylation of heteroarenes, see: (a) Ackermann, L.; Vicente, R.; Kapdi, A. R. *Angew. Chem., Int. Ed.* **2009**, *48*, 9792–9826. (b) Bellina, F.; Rossi, R. *Tetrahedron* **2009**, *65*, 10269–10310.
- (14) (a) Liégault, B.; Lapointe, D.; Caron, L.; Vlassova, A.; Fagnou, K. *J. Org. Chem.* **2009**, *74*, 1826–1834. (b) Liégault, B.; Petrov, I.; Gorelsky, S. I.; Fagnou, K. *J. Org. Chem.* **2010**, *75*, 1047–1060, and references cited therein.

Graphical Abstract

Short Title: Palladium-Catalyzed Cascade Cyclization through Direct Arylation